Researchers examined 19,978 UC patients and 13,005 Crohn’s disease patients.
• 80 percent of UC and Crohn’s disease patients had one or more suboptimal therapy marker
• Total costs per Crohn’s disease patient were significantly higher ($18,736) with suboptimal therapy markers compared to patients without suboptimal markers ($10,878)
• Total costs per UC patient with suboptimal therapy markers was $12,679 compared to $9,653 in UC patients without suboptimal markers
More Articles on Gastroenterology:
GI in the News: 6 Gastroenterologist Moves & Honors
5 Things to Know About Removing Barriers to Colorectal Cancer Screening Act
Radiofrequency Therapy for GERD: DDW Panel Snapshot
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
